Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Leases: 2021-2024

Historic Current Leases for Nurix Therapeutics (NRIX) over the last 4 years, with Nov 2024 value amounting to $8.0 million.

  • Nurix Therapeutics' Current Leases fell 42.15% to $3.8 million in Q3 2025 from the same period last year, while for Aug 2025 it was $3.8 million, marking a year-over-year decrease of 42.15%. This contributed to the annual value of $8.0 million for FY2024, which is 7.01% up from last year.
  • As of FY2024, Nurix Therapeutics' Current Leases stood at $8.0 million, which was up 7.01% from $7.5 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Current Leases peaked at $8.0 million during FY2024, and registered a low of $3.8 million during FY2021.
  • For the 3-year period, Nurix Therapeutics' Current Leases averaged around $7.0 million, with its median value being $7.5 million (2023).
  • Data for Nurix Therapeutics' Current Leases shows a peak YoY spiked of 43.75% (in 2022) over the last 5 years.
  • Over the past 4 years, Nurix Therapeutics' Current Leases (Yearly) stood at $3.8 million in 2021, then surged by 43.75% to $5.5 million in 2022, then skyrocketed by 35.42% to $7.5 million in 2023, then grew by 7.01% to $8.0 million in 2024.